Our Ambitions

100 Assays Through Our Assay Accelerator by 2029

Vidiia is transforming assay development and on-site diagnostics with innovative AI technology. By 2029, we aim to accelerate 100 assays through our Assay Accelerator.

Our platform leverages AI to turn academic research into impactful, cost-effective diagnostics, identifying and unlocking dormant or unknown assays.

We are committed to democratising diagnostic testing with low-cost, portable, AI-powered solutions that can be used anywhere, by anyone.

Vidiia identify the need to bridge research and real-world application, enhancing efficiency and ensuring global accessibility, setting new industry standards in diagnostic innovation.

About Vidiia

A game-changing team of medical, technology and operational experts brought together in 2020 to pursue a new breed of low cost disease diagnostics deployable anywhere in the field, by anyone.

Collaborating with leading molecular biotech universities – our purpose is to accelerate diagnostic development, enabling small scale, smart, remote disease testing using Vidiia’s AI-powered technologies.

Our range of scalable testing technologies and products are simple to use, fast, accurate and secure.

David Rimer

CEO and Cofounder

Mark Bullen

CTO and Cofounder

Dr Will Lovegrove

Director of Innovation Strategy at University of Surrey

Professor Roberto La Ragione

Head of School of Biosciences and Medicine at the University of Surrey

Averil Horton

Head of Business Development & Innovation at Brunel University London

Professor Wamadeva Balachandran

Professor Wamadeva Balachandran

Dr. Aurore Poirier

Head of Science

Jessie Carpenter

Project Manager and R&D expert

Ruben Dario Riano Moreno

Chief Digital Innovator

Charlie Worsley

Business Development Director

Vision

Accesible , Portable, AI-Driven Testing

Mission

Testing by anyone, anywhere, anytime